nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—AOX1—Methotrexate—testicular cancer	0.192	0.292	CbGbCtD
Zaleplon—CYP3A7—Ifosfamide—testicular cancer	0.123	0.187	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.123	0.187	CbGbCtD
Zaleplon—CYP3A5—Ifosfamide—testicular cancer	0.0922	0.14	CbGbCtD
Zaleplon—CYP3A5—Etoposide—testicular cancer	0.0441	0.0669	CbGbCtD
Zaleplon—CYP3A4—Ifosfamide—testicular cancer	0.036	0.0546	CbGbCtD
Zaleplon—CYP3A4—Vinblastine—testicular cancer	0.0191	0.029	CbGbCtD
Zaleplon—CYP3A4—Etoposide—testicular cancer	0.0172	0.0261	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—testicular cancer	0.0117	0.0178	CbGbCtD
Zaleplon—Pain—Cisplatin—testicular cancer	0.000256	0.00075	CcSEcCtD
Zaleplon—Dermatitis—Bleomycin—testicular cancer	0.000256	0.00075	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000256	0.000748	CcSEcCtD
Zaleplon—Muscular weakness—Doxorubicin—testicular cancer	0.000256	0.000748	CcSEcCtD
Zaleplon—Dysuria—Epirubicin—testicular cancer	0.000253	0.000741	CcSEcCtD
Zaleplon—Stomatitis—Methotrexate—testicular cancer	0.000251	0.000736	CcSEcCtD
Zaleplon—Conjunctivitis—Methotrexate—testicular cancer	0.000251	0.000734	CcSEcCtD
Zaleplon—Dysphagia—Doxorubicin—testicular cancer	0.00025	0.000733	CcSEcCtD
Zaleplon—Asthma—Doxorubicin—testicular cancer	0.00025	0.000733	CcSEcCtD
Zaleplon—Pollakiuria—Epirubicin—testicular cancer	0.00025	0.000732	CcSEcCtD
Zaleplon—Asthenia—Ifosfamide—testicular cancer	0.000249	0.00073	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—testicular cancer	0.000248	0.000726	CcSEcCtD
Zaleplon—Sweating—Methotrexate—testicular cancer	0.000247	0.000724	CcSEcCtD
Zaleplon—Photosensitivity reaction—Epirubicin—testicular cancer	0.000247	0.000723	CcSEcCtD
Zaleplon—Feeling abnormal—Cisplatin—testicular cancer	0.000247	0.000723	CcSEcCtD
Zaleplon—Paraesthesia—Etoposide—testicular cancer	0.000247	0.000722	CcSEcCtD
Zaleplon—Weight increased—Epirubicin—testicular cancer	0.000246	0.000721	CcSEcCtD
Zaleplon—Pruritus—Ifosfamide—testicular cancer	0.000246	0.00072	CcSEcCtD
Zaleplon—Haematuria—Methotrexate—testicular cancer	0.000246	0.00072	CcSEcCtD
Zaleplon—Weight decreased—Epirubicin—testicular cancer	0.000245	0.000717	CcSEcCtD
Zaleplon—Dyspnoea—Etoposide—testicular cancer	0.000245	0.000717	CcSEcCtD
Zaleplon—Hyperglycaemia—Epirubicin—testicular cancer	0.000244	0.000715	CcSEcCtD
Zaleplon—Somnolence—Etoposide—testicular cancer	0.000244	0.000715	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—testicular cancer	0.000244	0.000714	CcSEcCtD
Zaleplon—Hepatobiliary disease—Methotrexate—testicular cancer	0.000244	0.000714	CcSEcCtD
Zaleplon—Epistaxis—Methotrexate—testicular cancer	0.000243	0.000712	CcSEcCtD
Zaleplon—Pneumonia—Epirubicin—testicular cancer	0.000243	0.000711	CcSEcCtD
Zaleplon—Nausea—Bleomycin—testicular cancer	0.000242	0.000707	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—testicular cancer	0.000241	0.000705	CcSEcCtD
Zaleplon—Rash—Dactinomycin—testicular cancer	0.000239	0.0007	CcSEcCtD
Zaleplon—Decreased appetite—Etoposide—testicular cancer	0.000239	0.000699	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Etoposide—testicular cancer	0.000237	0.000694	CcSEcCtD
Zaleplon—Body temperature increased—Cisplatin—testicular cancer	0.000237	0.000694	CcSEcCtD
Zaleplon—Neuropathy peripheral—Epirubicin—testicular cancer	0.000237	0.000693	CcSEcCtD
Zaleplon—Stomatitis—Epirubicin—testicular cancer	0.000235	0.000689	CcSEcCtD
Zaleplon—Constipation—Etoposide—testicular cancer	0.000235	0.000687	CcSEcCtD
Zaleplon—Pain—Etoposide—testicular cancer	0.000235	0.000687	CcSEcCtD
Zaleplon—Conjunctivitis—Epirubicin—testicular cancer	0.000235	0.000687	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—testicular cancer	0.000234	0.000686	CcSEcCtD
Zaleplon—Sweating—Epirubicin—testicular cancer	0.000231	0.000677	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—testicular cancer	0.000231	0.000677	CcSEcCtD
Zaleplon—Haematuria—Epirubicin—testicular cancer	0.00023	0.000674	CcSEcCtD
Zaleplon—Dizziness—Ifosfamide—testicular cancer	0.00023	0.000673	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000229	0.000669	CcSEcCtD
Zaleplon—Hepatobiliary disease—Epirubicin—testicular cancer	0.000228	0.000668	CcSEcCtD
Zaleplon—Weight increased—Doxorubicin—testicular cancer	0.000228	0.000667	CcSEcCtD
Zaleplon—Epistaxis—Epirubicin—testicular cancer	0.000228	0.000666	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—testicular cancer	0.000227	0.000663	CcSEcCtD
Zaleplon—Feeling abnormal—Etoposide—testicular cancer	0.000226	0.000662	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—testicular cancer	0.000226	0.000661	CcSEcCtD
Zaleplon—Nausea—Dactinomycin—testicular cancer	0.000225	0.00066	CcSEcCtD
Zaleplon—Pneumonia—Doxorubicin—testicular cancer	0.000225	0.000657	CcSEcCtD
Zaleplon—Gastrointestinal pain—Etoposide—testicular cancer	0.000225	0.000657	CcSEcCtD
Zaleplon—Visual impairment—Methotrexate—testicular cancer	0.000223	0.000653	CcSEcCtD
Zaleplon—Rash—Ifosfamide—testicular cancer	0.000219	0.000642	CcSEcCtD
Zaleplon—Dermatitis—Ifosfamide—testicular cancer	0.000219	0.000641	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000219	0.000641	CcSEcCtD
Zaleplon—Urticaria—Etoposide—testicular cancer	0.000218	0.000639	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—testicular cancer	0.000218	0.000637	CcSEcCtD
Zaleplon—Abdominal pain—Etoposide—testicular cancer	0.000217	0.000635	CcSEcCtD
Zaleplon—Body temperature increased—Etoposide—testicular cancer	0.000217	0.000635	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—testicular cancer	0.000217	0.000635	CcSEcCtD
Zaleplon—Eye disorder—Methotrexate—testicular cancer	0.000216	0.000633	CcSEcCtD
Zaleplon—Tinnitus—Methotrexate—testicular cancer	0.000216	0.000632	CcSEcCtD
Zaleplon—Hypoaesthesia—Epirubicin—testicular cancer	0.000216	0.000631	CcSEcCtD
Zaleplon—Asthenia—Cisplatin—testicular cancer	0.000215	0.00063	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—testicular cancer	0.000214	0.000627	CcSEcCtD
Zaleplon—Oedema peripheral—Epirubicin—testicular cancer	0.000213	0.000625	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—testicular cancer	0.000213	0.000623	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000211	0.000618	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—testicular cancer	0.000211	0.000617	CcSEcCtD
Zaleplon—Immune system disorder—Methotrexate—testicular cancer	0.000209	0.000612	CcSEcCtD
Zaleplon—Visual impairment—Epirubicin—testicular cancer	0.000209	0.000611	CcSEcCtD
Zaleplon—Chills—Methotrexate—testicular cancer	0.000208	0.000608	CcSEcCtD
Zaleplon—Nausea—Ifosfamide—testicular cancer	0.000206	0.000605	CcSEcCtD
Zaleplon—Alopecia—Methotrexate—testicular cancer	0.000205	0.000599	CcSEcCtD
Zaleplon—Mental disorder—Methotrexate—testicular cancer	0.000203	0.000594	CcSEcCtD
Zaleplon—Eye disorder—Epirubicin—testicular cancer	0.000202	0.000593	CcSEcCtD
Zaleplon—Tinnitus—Epirubicin—testicular cancer	0.000202	0.000591	CcSEcCtD
Zaleplon—Malnutrition—Methotrexate—testicular cancer	0.000202	0.00059	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—testicular cancer	0.000199	0.000584	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—testicular cancer	0.000197	0.000578	CcSEcCtD
Zaleplon—Dysgeusia—Methotrexate—testicular cancer	0.000197	0.000578	CcSEcCtD
Zaleplon—Asthenia—Etoposide—testicular cancer	0.000197	0.000577	CcSEcCtD
Zaleplon—Immune system disorder—Epirubicin—testicular cancer	0.000196	0.000573	CcSEcCtD
Zaleplon—Back pain—Methotrexate—testicular cancer	0.000195	0.000571	CcSEcCtD
Zaleplon—Chills—Epirubicin—testicular cancer	0.000194	0.000569	CcSEcCtD
Zaleplon—Pruritus—Etoposide—testicular cancer	0.000194	0.000569	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—testicular cancer	0.000193	0.000566	CcSEcCtD
Zaleplon—Alopecia—Epirubicin—testicular cancer	0.000191	0.00056	CcSEcCtD
Zaleplon—Mental disorder—Epirubicin—testicular cancer	0.00019	0.000556	CcSEcCtD
Zaleplon—Rash—Cisplatin—testicular cancer	0.000189	0.000553	CcSEcCtD
Zaleplon—Dermatitis—Cisplatin—testicular cancer	0.000189	0.000553	CcSEcCtD
Zaleplon—Malnutrition—Epirubicin—testicular cancer	0.000189	0.000552	CcSEcCtD
Zaleplon—Eye disorder—Doxorubicin—testicular cancer	0.000187	0.000548	CcSEcCtD
Zaleplon—Ill-defined disorder—Methotrexate—testicular cancer	0.000187	0.000547	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—testicular cancer	0.000187	0.000547	CcSEcCtD
Zaleplon—Anaemia—Methotrexate—testicular cancer	0.000186	0.000545	CcSEcCtD
Zaleplon—Flatulence—Epirubicin—testicular cancer	0.000186	0.000544	CcSEcCtD
Zaleplon—Tension—Epirubicin—testicular cancer	0.000185	0.000542	CcSEcCtD
Zaleplon—Dysgeusia—Epirubicin—testicular cancer	0.000185	0.000541	CcSEcCtD
Zaleplon—Nervousness—Epirubicin—testicular cancer	0.000183	0.000536	CcSEcCtD
Zaleplon—Back pain—Epirubicin—testicular cancer	0.000182	0.000534	CcSEcCtD
Zaleplon—Malaise—Methotrexate—testicular cancer	0.000182	0.000532	CcSEcCtD
Zaleplon—Dizziness—Etoposide—testicular cancer	0.000182	0.000532	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—testicular cancer	0.000181	0.00053	CcSEcCtD
Zaleplon—Vertigo—Methotrexate—testicular cancer	0.000181	0.00053	CcSEcCtD
Zaleplon—Chills—Doxorubicin—testicular cancer	0.00018	0.000527	CcSEcCtD
Zaleplon—Nausea—Cisplatin—testicular cancer	0.000178	0.000521	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—testicular cancer	0.000177	0.000519	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—testicular cancer	0.000176	0.000514	CcSEcCtD
Zaleplon—Ill-defined disorder—Epirubicin—testicular cancer	0.000175	0.000512	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—testicular cancer	0.000174	0.000511	CcSEcCtD
Zaleplon—Anaemia—Epirubicin—testicular cancer	0.000174	0.00051	CcSEcCtD
Zaleplon—Agitation—Epirubicin—testicular cancer	0.000173	0.000507	CcSEcCtD
Zaleplon—Rash—Etoposide—testicular cancer	0.000173	0.000507	CcSEcCtD
Zaleplon—Dermatitis—Etoposide—testicular cancer	0.000173	0.000506	CcSEcCtD
Zaleplon—Headache—Etoposide—testicular cancer	0.000172	0.000504	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—testicular cancer	0.000172	0.000503	CcSEcCtD
Zaleplon—Chest pain—Methotrexate—testicular cancer	0.000172	0.000502	CcSEcCtD
Zaleplon—Myalgia—Methotrexate—testicular cancer	0.000172	0.000502	CcSEcCtD
Zaleplon—Arthralgia—Methotrexate—testicular cancer	0.000172	0.000502	CcSEcCtD
Zaleplon—Tension—Doxorubicin—testicular cancer	0.000171	0.000501	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—testicular cancer	0.000171	0.0005	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00017	0.000499	CcSEcCtD
Zaleplon—Malaise—Epirubicin—testicular cancer	0.00017	0.000498	CcSEcCtD
Zaleplon—Discomfort—Methotrexate—testicular cancer	0.000169	0.000496	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—testicular cancer	0.000169	0.000496	CcSEcCtD
Zaleplon—Vertigo—Epirubicin—testicular cancer	0.000169	0.000496	CcSEcCtD
Zaleplon—Syncope—Epirubicin—testicular cancer	0.000169	0.000495	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—testicular cancer	0.000169	0.000494	CcSEcCtD
Zaleplon—Palpitations—Epirubicin—testicular cancer	0.000167	0.000488	CcSEcCtD
Zaleplon—Confusional state—Methotrexate—testicular cancer	0.000166	0.000485	CcSEcCtD
Zaleplon—Loss of consciousness—Epirubicin—testicular cancer	0.000166	0.000485	CcSEcCtD
Zaleplon—Anaphylactic shock—Methotrexate—testicular cancer	0.000164	0.000481	CcSEcCtD
Zaleplon—Nausea—Etoposide—testicular cancer	0.000163	0.000477	CcSEcCtD
Zaleplon—Hypertension—Epirubicin—testicular cancer	0.000163	0.000477	CcSEcCtD
Zaleplon—Ill-defined disorder—Doxorubicin—testicular cancer	0.000162	0.000474	CcSEcCtD
Zaleplon—Nervous system disorder—Methotrexate—testicular cancer	0.000161	0.000472	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—testicular cancer	0.000161	0.000472	CcSEcCtD
Zaleplon—Myalgia—Epirubicin—testicular cancer	0.000161	0.00047	CcSEcCtD
Zaleplon—Chest pain—Epirubicin—testicular cancer	0.000161	0.00047	CcSEcCtD
Zaleplon—Arthralgia—Epirubicin—testicular cancer	0.000161	0.00047	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—testicular cancer	0.00016	0.000469	CcSEcCtD
Zaleplon—Anxiety—Epirubicin—testicular cancer	0.00016	0.000468	CcSEcCtD
Zaleplon—Skin disorder—Methotrexate—testicular cancer	0.00016	0.000468	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000159	0.000467	CcSEcCtD
Zaleplon—Hyperhidrosis—Methotrexate—testicular cancer	0.000159	0.000465	CcSEcCtD
Zaleplon—Discomfort—Epirubicin—testicular cancer	0.000159	0.000464	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—testicular cancer	0.000157	0.000461	CcSEcCtD
Zaleplon—Dry mouth—Epirubicin—testicular cancer	0.000157	0.00046	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—testicular cancer	0.000157	0.000459	CcSEcCtD
Zaleplon—Anorexia—Methotrexate—testicular cancer	0.000157	0.000459	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—testicular cancer	0.000156	0.000458	CcSEcCtD
Zaleplon—Confusional state—Epirubicin—testicular cancer	0.000155	0.000454	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—testicular cancer	0.000154	0.000451	CcSEcCtD
Zaleplon—Anaphylactic shock—Epirubicin—testicular cancer	0.000154	0.000451	CcSEcCtD
Zaleplon—Oedema—Epirubicin—testicular cancer	0.000154	0.000451	CcSEcCtD
Zaleplon—Hypotension—Methotrexate—testicular cancer	0.000154	0.00045	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—testicular cancer	0.000153	0.000449	CcSEcCtD
Zaleplon—Shock—Epirubicin—testicular cancer	0.000151	0.000443	CcSEcCtD
Zaleplon—Nervous system disorder—Epirubicin—testicular cancer	0.000151	0.000442	CcSEcCtD
Zaleplon—Hypertension—Doxorubicin—testicular cancer	0.000151	0.000441	CcSEcCtD
Zaleplon—Tachycardia—Epirubicin—testicular cancer	0.00015	0.00044	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00015	0.000439	CcSEcCtD
Zaleplon—Skin disorder—Epirubicin—testicular cancer	0.000149	0.000438	CcSEcCtD
Zaleplon—Hyperhidrosis—Epirubicin—testicular cancer	0.000149	0.000436	CcSEcCtD
Zaleplon—Insomnia—Methotrexate—testicular cancer	0.000149	0.000435	CcSEcCtD
Zaleplon—Chest pain—Doxorubicin—testicular cancer	0.000149	0.000435	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—testicular cancer	0.000149	0.000435	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—testicular cancer	0.000149	0.000435	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—testicular cancer	0.000148	0.000433	CcSEcCtD
Zaleplon—Paraesthesia—Methotrexate—testicular cancer	0.000148	0.000432	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000148	0.000432	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—testicular cancer	0.000147	0.00043	CcSEcCtD
Zaleplon—Anorexia—Epirubicin—testicular cancer	0.000147	0.000429	CcSEcCtD
Zaleplon—Dyspnoea—Methotrexate—testicular cancer	0.000147	0.000429	CcSEcCtD
Zaleplon—Somnolence—Methotrexate—testicular cancer	0.000146	0.000428	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—testicular cancer	0.000145	0.000425	CcSEcCtD
Zaleplon—Dyspepsia—Methotrexate—testicular cancer	0.000145	0.000424	CcSEcCtD
Zaleplon—Hypotension—Epirubicin—testicular cancer	0.000144	0.000421	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—testicular cancer	0.000144	0.00042	CcSEcCtD
Zaleplon—Decreased appetite—Methotrexate—testicular cancer	0.000143	0.000419	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—testicular cancer	0.000142	0.000417	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—testicular cancer	0.000142	0.000417	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000142	0.000416	CcSEcCtD
Zaleplon—Pain—Methotrexate—testicular cancer	0.000141	0.000412	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00014	0.000411	CcSEcCtD
Zaleplon—Shock—Doxorubicin—testicular cancer	0.00014	0.00041	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—testicular cancer	0.00014	0.000409	CcSEcCtD
Zaleplon—Insomnia—Epirubicin—testicular cancer	0.000139	0.000408	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—testicular cancer	0.000139	0.000407	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—testicular cancer	0.000138	0.000405	CcSEcCtD
Zaleplon—Paraesthesia—Epirubicin—testicular cancer	0.000138	0.000405	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—testicular cancer	0.000138	0.000403	CcSEcCtD
Zaleplon—Dyspnoea—Epirubicin—testicular cancer	0.000137	0.000402	CcSEcCtD
Zaleplon—Somnolence—Epirubicin—testicular cancer	0.000137	0.000401	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—testicular cancer	0.000136	0.000397	CcSEcCtD
Zaleplon—Feeling abnormal—Methotrexate—testicular cancer	0.000136	0.000397	CcSEcCtD
Zaleplon—Dyspepsia—Epirubicin—testicular cancer	0.000135	0.000397	CcSEcCtD
Zaleplon—Gastrointestinal pain—Methotrexate—testicular cancer	0.000134	0.000394	CcSEcCtD
Zaleplon—Decreased appetite—Epirubicin—testicular cancer	0.000134	0.000392	CcSEcCtD
Zaleplon—Hypotension—Doxorubicin—testicular cancer	0.000133	0.00039	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000133	0.000389	CcSEcCtD
Zaleplon—Pain—Epirubicin—testicular cancer	0.000132	0.000385	CcSEcCtD
Zaleplon—Constipation—Epirubicin—testicular cancer	0.000132	0.000385	CcSEcCtD
Zaleplon—Urticaria—Methotrexate—testicular cancer	0.000131	0.000382	CcSEcCtD
Zaleplon—Abdominal pain—Methotrexate—testicular cancer	0.00013	0.000381	CcSEcCtD
Zaleplon—Body temperature increased—Methotrexate—testicular cancer	0.00013	0.000381	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00013	0.00038	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—testicular cancer	0.000129	0.000377	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—testicular cancer	0.000128	0.000374	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—testicular cancer	0.000127	0.000372	CcSEcCtD
Zaleplon—Feeling abnormal—Epirubicin—testicular cancer	0.000127	0.000371	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—testicular cancer	0.000127	0.000371	CcSEcCtD
Zaleplon—Gastrointestinal pain—Epirubicin—testicular cancer	0.000126	0.000368	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—testicular cancer	0.000125	0.000367	CcSEcCtD
Zaleplon—Decreased appetite—Doxorubicin—testicular cancer	0.000124	0.000362	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000123	0.00036	CcSEcCtD
Zaleplon—Urticaria—Epirubicin—testicular cancer	0.000122	0.000358	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—testicular cancer	0.000122	0.000357	CcSEcCtD
Zaleplon—Pain—Doxorubicin—testicular cancer	0.000122	0.000357	CcSEcCtD
Zaleplon—Abdominal pain—Epirubicin—testicular cancer	0.000122	0.000356	CcSEcCtD
Zaleplon—Body temperature increased—Epirubicin—testicular cancer	0.000122	0.000356	CcSEcCtD
Zaleplon—Asthenia—Methotrexate—testicular cancer	0.000118	0.000345	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—testicular cancer	0.000117	0.000344	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000116	0.000341	CcSEcCtD
Zaleplon—Pruritus—Methotrexate—testicular cancer	0.000116	0.000341	CcSEcCtD
Zaleplon—Urticaria—Doxorubicin—testicular cancer	0.000113	0.000331	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—testicular cancer	0.000113	0.00033	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—testicular cancer	0.000113	0.00033	CcSEcCtD
Zaleplon—Asthenia—Epirubicin—testicular cancer	0.00011	0.000323	CcSEcCtD
Zaleplon—Pruritus—Epirubicin—testicular cancer	0.000109	0.000319	CcSEcCtD
Zaleplon—Dizziness—Methotrexate—testicular cancer	0.000109	0.000318	CcSEcCtD
Zaleplon—Rash—Methotrexate—testicular cancer	0.000104	0.000304	CcSEcCtD
Zaleplon—Dermatitis—Methotrexate—testicular cancer	0.000104	0.000303	CcSEcCtD
Zaleplon—Headache—Methotrexate—testicular cancer	0.000103	0.000302	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—testicular cancer	0.000102	0.000299	CcSEcCtD
Zaleplon—Dizziness—Epirubicin—testicular cancer	0.000102	0.000298	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—testicular cancer	0.000101	0.000295	CcSEcCtD
Zaleplon—Nausea—Methotrexate—testicular cancer	9.77e-05	0.000286	CcSEcCtD
Zaleplon—Rash—Epirubicin—testicular cancer	9.7e-05	0.000284	CcSEcCtD
Zaleplon—Dermatitis—Epirubicin—testicular cancer	9.69e-05	0.000284	CcSEcCtD
Zaleplon—Headache—Epirubicin—testicular cancer	9.64e-05	0.000282	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—testicular cancer	9.42e-05	0.000276	CcSEcCtD
Zaleplon—Nausea—Epirubicin—testicular cancer	9.14e-05	0.000268	CcSEcCtD
Zaleplon—Rash—Doxorubicin—testicular cancer	8.98e-05	0.000263	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—testicular cancer	8.97e-05	0.000263	CcSEcCtD
Zaleplon—Headache—Doxorubicin—testicular cancer	8.92e-05	0.000261	CcSEcCtD
Zaleplon—Nausea—Doxorubicin—testicular cancer	8.46e-05	0.000248	CcSEcCtD
